Project: Preventing cancer therapy resistance and relapse: First-in-class therapy to inhibit DNA mutagenesis
| Acronym | ANTILAPSE (Reference Number: 114692) |
| Duration | 01/04/2021 - 01/04/2024 |
| Project Topic | ANTILAPSE will deliver a first-in-class drug to treat ovarian cancer patients by preventing development of therapeutic resistance and relapse. The drug prevents cancer-cell mutagenesis by inhibiting a key enzyme driving genomic instability. It will be developed as a combination and maintenance therapy to improve poor survival rates. We will deliver data packages required for subsequent regulatory pre- and clinical validation, completing ANTILAPSE with lead candidates ready for GLP-tox studies. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |